In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...
The U.S. Food and Drug Administration (FDA), and the Office of Human Research protections (OHRP) released draft guidance titled, “Considerations ...
GenAI-powered solution delivers clinical study reports in minutes with 30%–50% faster turnarounds, 90% ICH-E3-aligned ...
The evolution of protocol management within eQMS represents another significant advance in clinical trials. Version control ...
These challenges pertaining to burnt-out healthcare employees have resulted in major clinical trial workflow issues, including the impact of patients’ willingness to participate in trials ...
Dr. Mrinal M Gounder emphasizes the complexity of breast cancer and the necessity for unique treatments for its many variants. The Jeevan project aims to overcome challenges in patient participation ...
Randomized controlled trials are clinical trials in which at least two interventions — the test treatment and a control treatment — are simultaneously evaluated in two or more arms of the ...
CARY, NORTH CAROLINA / ACCESS Newswire / January 30, 2025 / Yunu, a leading provider of clinical trial imaging workflow and data management solutions, is pleased to announce its partnership with ...
CARY, NORTH CAROLINA / ACCESS Newswire / January 30, 2025 / Yunu, a leading provider of clinical trial imaging workflow and data management solutions, is pleased to announce its partnership with WCG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback